Status:

UNKNOWN

The Efficacy and Safety of TBCB vs TBFB in Diagnosis of GGO

Lead Sponsor:

Shanghai Chest Hospital

Collaborating Sponsors:

First Affiliated Hospital of Chongqing Medical University

Conditions:

Lung Ground-Glass Opacity

Eligibility:

All Genders

18-80 years

Phase:

NA

Brief Summary

The aim of this study is to investigate the difference of efficacy and safety between transbronchial cryobiopsy (TBCB) and transbronchial forceps biopsy (TBFB) in the diagnosis of lung ground-glass op...

Detailed Description

The conventional biopsy method for lung ground-glass opacity (GGO) diagnosis is to use disposable guided sheath (including biopsy forceps and cell brushes) which have some limitations, such as big phy...

Eligibility Criteria

Inclusion

  • Male or female aged between 18 and 80.
  • CT or other imaging examination suggest a tendency towards malignant GGO (size ≥ 8 mm). The ground glass composition is more than 50%.
  • Thin-slice CT scan with bronchial access or adjacent lesions.
  • Multidisciplinary assessment suggest that bronchopulmonary biopsy is needed to identify the pathological features of GGO.
  • It is suitable for pathological biopsy by transbronchial cryobiopsy or forceps biopsy.
  • Ability to read, understand and sign ICF.

Exclusion

  • Disseminated GGO, suspected of benign or infectious lesions.
  • Preoperative imaging examination showed that the biopsy lesion was adjacent to the middle or large vessels.
  • There are contraindications for bronchoscopy, such as irreparable coagulation dysfunction, severe cardiopulmonary insufficiency.
  • Intolerance or difficulty in cooperating with bronchoscopy, etc.
  • Routine bronchoscopic abnormalities, such as endoscopic lesions, external pressure, mucosal lesions, stenosis, hemorrhage, etc.
  • Vulnerable groups, such as pregnant women, etc.
  • Some other special situations investigator consider subjects are not suitable to participant in this study.

Key Trial Info

Start Date :

March 1 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 30 2021

Estimated Enrollment :

184 Patients enrolled

Trial Details

Trial ID

NCT04727190

Start Date

March 1 2021

End Date

December 30 2021

Last Update

February 2 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Shanghai Chest Hospital

Shanghai, Shanghai Municipality, China